Our observations support an important role for TFEB in the pathogenesis PD/DLB, thereby confirming the potential of targeting TFEB as a possible approach for urgently-required disease-modifying therapies for synucleinopathies. The gene discussed is TFEB; the disease is Parkinson disease.